Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
2(25%)
Results Posted
100%(4 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
1
13%
Ph phase_2
1
13%
Ph phase_3
4
50%
Ph not_applicable
1
13%

Phase Distribution

1

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
4(57.1%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Terminated1
unknown1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 21 (14.3%)
Phase 34 (57.1%)
N/A1 (14.3%)

Trials by Status

completed450%
terminated113%
unknown113%
recruiting113%
active_not_recruiting113%

Recent Activity

2 active trials
Showing 5 of 8
recruitingphase_3

Cardiac Sarcoidosis Randomized Trial

NCT03593759
active_not_recruitingphase_3

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166
terminatedphase_1

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT05295927
completedphase_2

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

NCT01972217
unknown

A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01834209
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03593759Phase 3

Cardiac Sarcoidosis Randomized Trial

Recruiting
NCT05288166Phase 3

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active Not Recruiting
NCT05295927Phase 1

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Terminated
NCT01972217Phase 2

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Completed
NCT01834209

A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Unknown
NCT01308580Phase 3

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Completed
NCT00519285Phase 3

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

Completed
NCT01451710Not Applicable

The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8